1-5 of 5
Hussam Saad
Close
Sort by
Journal Articles

CDKN2C Deletion on 1p32 Locus As Part of Irwazh Score, a New Risk Assessment Model for Venous Thromboembolism Occurring within 6-12 Months of Treatment Initiation in Newly Diagnosed Multiple Myeloma

Jean-Richard Eveillard, Nathalie Douet-Guilbert, Audrey Basinko, Romuald Kerdoncuff, Adrian Tempescul, Hussam Saad, Charazed Bekara, Zoé Bezagu, Moriamo Eniafe-Eveillard, Christophe Nicol, Jean-Christophe Ianotto
Journal: Blood
Blood (2023) 142 (Supplement 1): 4735.
https://doi.org/10.1182/blood-2023-179557
Published: 2023
Journal Articles

Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial

Laura Bounaix, Andrei Tchirkov, MD PhD, Florence Nguyen-Khac, MD PhD, Patricia Combes, Pierre Feugier, MD, Laurence Sanhes, Marie-Sarah Dilhuydy, MD, Hussam Saad, MD, Loic Ysebaert, MD PhD, Choquet Sylvain, Jean-Pierre Vilque, Annie Brion, Carla Araujo, MD, Emmanuelle Ferrant, Brigitte Dreyfus, Alain Jacques Delmer, MD, Malgorzata Truchan-Graczyk, Stéphane Leprêtre, MD, Sophie de Guibert, Romain Guieze, MD PhD, Lauren Veronese, MD PhD, Richard Lemal, MD, Philippe Vago, Jacques-Olivier Bay, MD PhD, Marc G. Berger, MD PhD, Anna Schuh, MD PhD, Christophe Ferrand, PhD, Roselyne Delepine, Véronique Leblond, Olivier Tournilhac, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4285.
https://doi.org/10.1182/blood.V130.Suppl_1.4285.4285
Published: 2017
Journal Articles

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Sophie de Guibert, MD, Marie-Sarah Dilhuydy, MD, Loic Ysebaert, Laurence Sanhès, MD, Sylvain Choquet, MD, Therese Aurran-Schleinitz, MD, Romain Guieze, MD, Beatrice Mahe, MD, Nicolas Daguindau, MD, Carla Araujo, MD, Hussam Saad, MD, Emmanuelle Ferrant, MD, Bruno Cazin, MD, Pierre Feugier, MD PhD, Brigitte Dreyfus, MD, Delmer Alain, MD, Stéphane Lepretre, MD, Magali Le Garff-Tavernier, PharmD, PhD, Véronese Lauren, MD, Anna Schuh, MDPhD, Bruno Pereira, Veronique Leblond, MD PhD, Olivier Tournilhac, MD
Journal: Blood
Blood (2014) 124 (21): 3341.
https://doi.org/10.1182/blood.V124.21.3341.3341
Published: 2014
Journal Articles

Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study

Jean-Richard Eveillard, MD, Jean-Christophe Ianotto, Adrian Tempescul, Gaelle Guillerm, Florence Dalbiès, Hussam Saad, MD, Ronan LE Calloc'h, Anaïg Dagorn, Françoise N'go Sack, Christian Berthou, MD
Journal: Blood
Blood (2011) 118 (21): 3066.
https://doi.org/10.1182/blood.V118.21.3066.3066
Published: 2011
Journal Articles

Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 In Poor-Risk DLBCL: Results of a Phase II Study

Jean-Richard Eveillard, MD, Jean-Christophe Ianotto, Adrian Tempescul, Gaelle Guillerm, Hussam Saad, MD, Florence Dalbiès, Ronan Le Calloch, Anaïg Dagorne, Christian Berthou
Journal: Blood
Blood (2010) 116 (21): 3558.
https://doi.org/10.1182/blood.V116.21.3558.3558
Published: 2010